The VA Portland Healthcare System (VHAPORHCS) Pathology & Laboratory Medicine Service Department requires continued access to specialized testing for Measurable Residual Disease (MRD) detection in hem... The VA Portland Healthcare System (VHAPORHCS) Pathology & Laboratory Medicine Service Department requires continued access to specialized testing for Measurable Residual Disease (MRD) detection in hematologic malignancies. MRD is a powerful diagnostic and prognostic tool that quantifies the presence of residual cancer cells during and after treatment in patients with multiple myeloma, B-cell acute lymphoblastic leukemia (B-ALL), and chronic lymphocytic leukemia (CLL).

The VA Portland Healthcare System requires a contractor to provide FDA-cleared, next-generation sequencing-based Measurable Residual Disease (MRD) testing for blood and bone marrow samples from patients with multiple myeloma, chronic lymphocytic leukemia, and B-cell acute lymphoblastic leukemia. Testing must be performed at the contractor’s CLIA-certified and CAP-accredited reference laboratory, with results reported within an average turnaround time of six business days. The contract includes five ordering periods from September 1, 2026, through August 31, 2031. The place of performance is the contractor’s reference laboratory as defined at award. The contractor must also provide all necessary supplies, technical support, and secure electronic reporting to VA clinicians.